Acasti Pharma Inc. (NASDAQ: ACST) Has Another Chance To Impress You


    With over 2.53 million Acasti Pharma Inc. (ACST) shares trading Friday and a closing price of $0.71 on the day, the dollar volume was approximately $1.8 million. The shares have shown a negative weekly performance of -7.32% and its price on 08/28/20 lost nearly -0.84%. Currently, there are 96.89M common shares owned by the public and among those 93.52M shares have been available to trade.

    An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 5 analysts who have offered their price forecasts for ACST have a consensus price objective of $2.78. The analysts have set the share’s price value over the next 12 months at a high of $7.00 and a low of $0.99 should the stock experience a downside. Incidentally, analysts’ outlook for the Acasti Pharma Inc. stock is 2.00 for the next 12 months. But an upside of 89.86% will see the stock hit the forecast high price target while mean target price for the stock is $2.15.

    The top 3 mutual fund holders in Acasti Pharma Inc. are Fidelity Nasdaq Composite Index F, Alma Capital Invt. Fds. – Apis Gl, and Series Portfolios Trust – Weiss A. Fidelity Nasdaq Composite Index F owns 61235.0 shares of the company’s stock, all valued at over $46539.0. Series Portfolios Trust – Weiss A sold 808.0 shares to bring its total holdings to over 0.0 shares at a value of $0.0. Series Portfolios Trust – Weiss A now owns shares totaling to 0.00% of the shares outstanding.

    Shares of Acasti Pharma Inc. (NASDAQ: ACST) opened at $0.715, up $0.01 from a prior closing price of $0.71. However, the script later closed the day at $0.71, down -0.84%. The company’s stock has a 5-day price change of -7.32% and 10.76% over the past three months. ACST shares are trading -71.06% year to date (YTD), with the 12-month market performance down to -60.83% lower. It has a 12-month low price of $0.25 and touched a high of $3.08 over the same period. Currently, 2.53 million shares have been traded, compared to an average intraday trading volume of 3.24 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.64%, 1.22%, and -23.57% respectively.

    Institutional ownership of Acasti Pharma Inc. (NASDAQ: ACST) shares accounts for 6.09% of the company’s 96.89M shares outstanding. Mutual fund holders own –, while other institutional holders and individual stakeholders account for — and — respectively.

    It has a market capitalization of $68.70M. The earnings-per-share (ttm) stands at -$0.24. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.04% over the week and 8.43% over the month.

    Analysts forecast that Acasti Pharma Inc. (ACST) will achieve an EPS of -$0.16 for the current quarter, $0 for the next quarter and -$0.35 for 2019. The lowest estimate earnings-per-share for the quarter is -$0.16 while analysts give the company a high EPS estimate of -$0.16. Earnings per share for the fiscal year are expected to increase by 30.30%, and 34.00% over the next financial year.

    If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate Acasti Pharma Inc. (ACST) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 0 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”

    Looking at the support for the ACST, a number of firms have released research notes about the stock. B. Riley FBR stated their Buy rating for the stock in a research note on July 06, 2020, with the firm’s price target at $2. B. Riley FBR coverage for the Acasti Pharma Inc. (ACST) stock in a research note released on January 13, 2020 offered a Neutral rating with a price target of. B. Riley FBR was of a view on August 29, 2019 that the stock is Buy, while Oppenheimer gave the stock Outperform rating on July 18, 2019, issuing a price target of $7. H.C. Wainwright on their part issued Buy rating on June 26, 2019.


    Please enter your comment!
    Please enter your name here